A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Identifieur interne : 003C42 ( Main/Curation ); précédent : 003C41; suivant : 003C43A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Auteurs : Xavier G. Thomas [France] ; Christopher Arthur [Australie] ; Jacques Delaunay [France] ; Mark Jones [États-Unis] ; Erhan Berrak [États-Unis] ; Hagop M. Kantarjian [États-Unis]Source :
- Clinical lymphoma, myeloma & leukemia [ 2152-2669 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antinéoplasiques antimétabolites (usage thérapeutique), Azacitidine (analogues et dérivés), Azacitidine (usage thérapeutique), Calendrier d'administration des médicaments, Femelle, Humains, Leucémie aigüe myéloïde (anatomopathologie), Leucémie aigüe myéloïde (traitement médicamenteux), Mâle, Pronostic, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
- MESH :
- analogues et dérivés : Azacitidine.
- anatomopathologie : Leucémie aigüe myéloïde.
- traitement médicamenteux : Leucémie aigüe myéloïde.
- usage thérapeutique : Antinéoplasiques antimétabolites, Azacitidine.
- Adulte d'âge moyen, Calendrier d'administration des médicaments, Femelle, Humains, Mâle, Pronostic, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antimetabolites, Antineoplastic (therapeutic use), Azacitidine (analogs & derivatives), Azacitidine (therapeutic use), Drug Administration Schedule, Female, Humans, Leukemia, Myeloid, Acute (drug therapy), Leukemia, Myeloid, Acute (pathology), Male, Middle Aged, Prognosis, Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Azacitidine.
- chemical , therapeutic use : Antimetabolites, Antineoplastic, Azacitidine.
- drug therapy : Leukemia, Myeloid, Acute.
- pathology : Leukemia, Myeloid, Acute.
- Aged, Aged, 80 and over, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prognosis, Treatment Outcome.
Abstract
In a multicenter, randomized, open-label phase III study, patients ≥ 65 years with newly diagnosed AML received decitabine 20 mg/m(2) once daily for 5 days every 4 weeks (n = 242) or treatment choice (supportive care or cytarabine 20 mg/m(2) once daily for 10 days every 4 weeks; n = 243). Decitabine use demonstrated greater response rates (P = .001) and OS data favored decitabine.
DOI: 10.1016/j.clml.2013.09.007
PubMed: 24220616
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003974
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003859
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003859
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001573
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001573
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001573
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003C93
Links to Exploration step
pubmed:24220616Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.</title><author><name sortKey="Thomas, Xavier G" sort="Thomas, Xavier G" uniqKey="Thomas X" first="Xavier G" last="Thomas">Xavier G. Thomas</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Lyon-Sud Hospital, Lyon, France. Electronic address: xavier.thomas@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Haematology, Lyon-Sud Hospital, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Arthur, Christopher" sort="Arthur, Christopher" uniqKey="Arthur C" first="Christopher" last="Arthur">Christopher Arthur</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Delaunay, Jacques" sort="Delaunay, Jacques" uniqKey="Delaunay J" first="Jacques" last="Delaunay">Jacques Delaunay</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Nantes University Hospital, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Haematology, Nantes University Hospital, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Jones, Mark" sort="Jones, Mark" uniqKey="Jones M" first="Mark" last="Jones">Mark Jones</name><affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, Eisai Inc, Woodcliff Lake, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Oncology, Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Berrak, Erhan" sort="Berrak, Erhan" uniqKey="Berrak E" first="Erhan" last="Berrak">Erhan Berrak</name><affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, Eisai Inc, Woodcliff Lake, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Oncology, Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name><affiliation wicri:level="2"><nlm:affiliation>Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24220616</idno><idno type="pmid">24220616</idno><idno type="doi">10.1016/j.clml.2013.09.007</idno><idno type="wicri:Area/PubMed/Corpus">003974</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003974</idno><idno type="wicri:Area/PubMed/Curation">003859</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003859</idno><idno type="wicri:Area/PubMed/Checkpoint">003859</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003859</idno><idno type="wicri:Area/Ncbi/Merge">001573</idno><idno type="wicri:Area/Ncbi/Curation">001573</idno><idno type="wicri:Area/Ncbi/Checkpoint">001573</idno><idno type="wicri:Area/Main/Merge">003C93</idno><idno type="wicri:Area/Main/Curation">003C42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.</title><author><name sortKey="Thomas, Xavier G" sort="Thomas, Xavier G" uniqKey="Thomas X" first="Xavier G" last="Thomas">Xavier G. Thomas</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Lyon-Sud Hospital, Lyon, France. Electronic address: xavier.thomas@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Haematology, Lyon-Sud Hospital, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Arthur, Christopher" sort="Arthur, Christopher" uniqKey="Arthur C" first="Christopher" last="Arthur">Christopher Arthur</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Delaunay, Jacques" sort="Delaunay, Jacques" uniqKey="Delaunay J" first="Jacques" last="Delaunay">Jacques Delaunay</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Nantes University Hospital, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Haematology, Nantes University Hospital, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Jones, Mark" sort="Jones, Mark" uniqKey="Jones M" first="Mark" last="Jones">Mark Jones</name><affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, Eisai Inc, Woodcliff Lake, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Oncology, Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Berrak, Erhan" sort="Berrak, Erhan" uniqKey="Berrak E" first="Erhan" last="Berrak">Erhan Berrak</name><affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, Eisai Inc, Woodcliff Lake, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Oncology, Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name><affiliation wicri:level="2"><nlm:affiliation>Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author></analytic><series><title level="j">Clinical lymphoma, myeloma & leukemia</title><idno type="eISSN">2152-2669</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antimetabolites, Antineoplastic (therapeutic use)</term><term>Azacitidine (analogs & derivatives)</term><term>Azacitidine (therapeutic use)</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Leukemia, Myeloid, Acute (drug therapy)</term><term>Leukemia, Myeloid, Acute (pathology)</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antinéoplasiques antimétabolites (usage thérapeutique)</term><term>Azacitidine (analogues et dérivés)</term><term>Azacitidine (usage thérapeutique)</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Leucémie aigüe myéloïde (anatomopathologie)</term><term>Leucémie aigüe myéloïde (traitement médicamenteux)</term><term>Mâle</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Azacitidine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Azacitidine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Azacitidine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Leucémie aigüe myéloïde</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myeloid, Acute</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Leukemia, Myeloid, Acute</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie aigüe myéloïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Azacitidine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a multicenter, randomized, open-label phase III study, patients ≥ 65 years with newly diagnosed AML received decitabine 20 mg/m(2) once daily for 5 days every 4 weeks (n = 242) or treatment choice (supportive care or cytarabine 20 mg/m(2) once daily for 10 days every 4 weeks; n = 243). Decitabine use demonstrated greater response rates (P = .001) and OS data favored decitabine.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003C42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:24220616
|texte= A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:24220616" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |